Current Headlines

  1. Certara Launches Version 8.2 Of Its Industry-Leading Phoenix PK/PD Modeling And Simulation Software For Drug Development
    9/12/2019

    Certara, the global model-informed drug development and decision support leader, recently announced the launch of Phoenix 8.2, the industry gold standard in pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation software for drug development

  2. Elite Pharmaceuticals Receives FDA Approval For Codeine And Acetaminophen Combo
    9/12/2019

    Elite Pharmaceuticals, Inc. ("Elite" or the "Company") a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, recently announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Tylenol with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets

  3. Hansoh Pharma And Atomwise Launch Strategic AI Drug Discovery Collaboration For Multiple Therapeutic Areas
    9/12/2019

    Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas

  4. Atomwise Announces Largest China-US Collaboration For AI Drug Discovery
    9/12/2019

    Atomwise Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, recently announced a collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas

  5. Puma Biotechnology Announces U.S. FDA Acceptance Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer
    9/11/2019

    Puma Biotechnology, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed therapy (third-line disease)

  6. Tubulis And Glycotope Announce Research And Feasibility Agreement For The Discovery Of Antibody Drug Conjugates
    9/11/2019

    Tubulis, a company developing uniquely matched protein drug conjugates, and Glycotope, a clinical-stage immuno-oncology company recently announced that they have signed a research and feasibility agreement, providing Glycotope access to Tubulis’ proprietary antibody drug conjugate (ADC) technologies

  7. SEngine Precision Medicine And Atomwise Announce Strategic Joint Venture To Accelerate Novel Drug Discovery
    9/10/2019

    SEngine Precision Medicine and Atomwise, Inc. recently announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development

  8. Acceleron Receives FDA Orphan Drug Designation For Sotatercept In Pulmonary Arterial Hypertension
    9/9/2019

    Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, recently announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH)

  9. Aptorum Group Announces The Development Of Microbiome Drug Candidate Targeting Obesity And Repurposed Drug Candidates Targeting Neuroblastoma
    9/9/2019

    Aptorum Group Limited (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively

  10. Two New Pfizer-Coauthored Studies Validate Novoheart’s Pioneering Human Bioengineered Heart Tissues And Chambers For Improving Drug Development
    9/9/2019

    Lab-grown heart tissues and chambers from Novoheart, (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, demonstrate advanced capabilities for drug screening as well as disease modeling which can lead to safer drugs with better efficacy, according to new research